Tag: preclinical

Researchers from Cleveland Clinic’s Global Center for Pathogen Research & Human Health have developed a promising new COVID-19 vaccine candidate that utilizes nanotechnology and has shown strong efficacy in preclinical disease models. According to new findings published in mBio, the vaccine produced potent neutralizing antibodies among preclinical models and also prevented infection and disease symptoms

New technology from Purdue University innovators may help improve tissue restoration outcomes for people with breast cancer and other diseases or traumatic injuries. Purdue researchers, along with fellowship-trained breast surgeon Carla Fisher of Indiana University School of Medicine, teamed up with Purdue startup GeniPhys to develop and perform preclinical studies on a regenerative tissue filler.

The University of Texas MD Anderson Cancer Center and Mirati Therapeutics, Inc. today announced a strategic research and development collaboration to expand the evaluation of Mirati's two investigational small molecules, potent and selective KRAS inhibitors – adagrasib (MRTX849), a G12C inhibitor in clinical development, and MRTX1133, a G12D inhibitor in preclinical development, as monotherapy and

The lung is a complex organ whose main function is to exchange gases. It is the largest organ in the human body and plays a key role in the oxygenation of all the organs. Due to its structure, cellular composition and dynamic microenvironment, is difficult to mimic in vitro. A specialized laboratory of the ARTORG

Adagio Therapeutics today published in vitro and in vivo data in Science on its lead antibody candidate, ADG2, which demonstrated similar or higher potency against SARS-CoV-2 compared to other monoclonal antibodies (mAbs) in clinical development and strong binding to all known SARS-CoV-2 variants. Uniquely, ADG2 also showed broad and potent neutralization against a range of

When it comes to vitamin D, most adults exhibit either frank deficiency, which results in clear clinical symptoms, or insufficiency, which often goes undetected. But how that insufficiency impacts physical health and the vulnerability of older adults to frailty as they age has been difficult to determine. Now a University at Buffalo study of 24-28–month-old

A COVID-19 vaccine candidate that underwent extensive preclinical testing at the University of Alabama at Birmingham this spring and summer shows potent preclinical immune responses—including several that distinguish it from other COVID-19 vaccine approaches—according to a preprint deposited in the BioRxiv repository this week. Partial preclinical results had been announced in July and August by

Scientists at The Wistar Institute and collaborators have successfully engineered novel DNA-encoded monoclonal antibodies (DMAbs) targeting Zaire Ebolavirus that were effective in preclinical models. Study results, published online in Cell Reports, showed that DMAbs were expressed over a wide window of time and offered complete and long-term protection against lethal virus challenges. DMAbs may also

FT819, an off-the-shelf, T-cell receptor (TCR)-less CD19 CAR T-cell product that could potentially be made more accessible to cancer patients than conventional CAR T-cell therapies showed positive results in preclinical specificity, functionality, and efficacy studies, according to data presented at the AACR Annual Meeting 2018, April 14-18. “Chimeric antigen receptor (CAR) T-cell therapy has shown